Galderma's New Restylane Syringe Cleared in EU, US and Canada for NASHA Lidocaine Range

Galderma said on October 21, 2026 that regulatory authorities in the EU, the U.S. and Canada approved a new state-of-the-art syringe for its NASHA lidocaine range of Restylane products, covering facial indications including the cheeks, nose, chin, jawline, tear troughs, nasolabial folds, marionette lines and the hands. Business Wire carried the announcement.

What Galderma's New Restylane Syringe Changes

The syringe features a next-generation ergonomic design, an optimized syringe-needle connection with the new Terumo K-Pack Enhance needle, and color-coded packaging and syringe design to support range navigation for practitioners. It was designed in collaboration with over 70 aesthetics practitioners and optimized for ergonomic functionality, ease of aspiration, ease of operation and a premium look and feel.

Galderma said the syringe was designed with sustainability in mind, using compact paper-only carton packaging that is 100% recyclable and reduces in-clinic waste by up to 30% based on volume reduction. The syringe is approved for use with Restylane Lyft Lidocaine, Restylane Eyelight and Restylane-L, known as Classyc Lidocaine in some markets.

"Developing this new syringe in close collaboration with practitioners to address their specific needs has really set it apart," said Dr. Luddi Luiz Oliveira, a plastic surgeon in Brazil. "Repetitive hand movements like performing numerous injections every day can lead to strain and reduced mobility, but the syringe's ergonomic design, with a cushioned finger grip and thumb rest ensure maximum comfort when injecting, supporting consistent, high-quality results for patients."

Baldo Scassellati Sforzolini, M.D., Ph.D., Galderma's global head of R&D, said the next-generation syringe reflects the latest advancements in injection design, giving aesthetic practitioners greater precision, improved ergonomics and enhanced control.

Galderma's Aesthetics Business at a Glance

Galderma is a global pure-play dermatology company selling injectable aesthetics, therapeutic dermatology drugs and consumer skincare to healthcare professionals and consumers across more than 90 countries, according to akta.pro company records. The same records show Galderma's Injectable Aesthetics business generated $648 million in revenue in the first quarter of 2026, a 13.1% increase, while total first-quarter net sales reached $1.473 billion, up 25.5% year on year at constant currency.

Restylane's Approvals and Milestones

Galderma marked 30 years since Restylane launched as the first hyaluronic acid injectable, FinanzNachrichten.de reported in October 2026, noting new approvals including Restylane Shaype for chin enhancement in the EU, a new syringe in the EU, U.S. and Canada, and Restylane Volyme for temple hollowing in the U.S. Galderma also received FDA approval for Restylane Contour for temple hollowing correction in March 2026, according to company records.

What Comes Next for the Restylane Syringe

The next-generation syringe is now approved for use in the EU, the U.S. and Canada with the NASHA lidocaine range of Restylane products. Galderma said Restylane has administered more than 77 million treatments worldwide over its 30-year history.